155 related articles for article (PubMed ID: 26406865)
1. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.
Nakashima M; Matsui Y; Kobayashi T; Saito R; Hatahira S; Kawakami K; Nakamura E; Nishiyama H; Ogawa O
Cancer Biomark; 2015; 15(4):357-64. PubMed ID: 26406865
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic role of urinary collagens in primary human bladder cancer.
Miyake M; Morizawa Y; Hori S; Tatsumi Y; Onishi S; Owari T; Iida K; Onishi K; Gotoh D; Nakai Y; Anai S; Chihara Y; Torimoto K; Aoki K; Tanaka N; Shimada K; Konishi N; Fujimoto K
Cancer Sci; 2017 Nov; 108(11):2221-2228. PubMed ID: 28837258
[TBL] [Abstract][Full Text] [Related]
3. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
[TBL] [Abstract][Full Text] [Related]
4. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
[TBL] [Abstract][Full Text] [Related]
5. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
9. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
10. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
11. Urinary levels of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.
Nitta Y; Konishi H; Makino T; Tanaka T; Kawashima H; Iovanna JL; Nakatani T; Kiyama H
BMC Urol; 2012 Sep; 12():24. PubMed ID: 22943287
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
Liu B; Miyake H; Nishikawa M; Fujisawa M
Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
[TBL] [Abstract][Full Text] [Related]
13. CXCL1 is elevated in the urine of bladder cancer patients.
Burnier A; Shimizu Y; Dai Y; Nakashima M; Matsui Y; Ogawa O; Rosser CJ; Furuya H
Springerplus; 2015; 4():610. PubMed ID: 26543745
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence.
Wu XX; Kakehi Y; Takahashi T; Habuchi T; Ogawa O
Int J Urol; 2000 Jun; 7(6):210-7. PubMed ID: 10843452
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
16. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
17. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis.
Dong F; Shen Y; Xu T; Wang X; Gao F; Zhong S; Chen S; Shen Z
World J Surg Oncol; 2018 Mar; 16(1):61. PubMed ID: 29562940
[TBL] [Abstract][Full Text] [Related]
19. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
[TBL] [Abstract][Full Text] [Related]
20. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
Urol Oncol; 2015 Feb; 33(2):66.e25-31. PubMed ID: 25037483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
